Novel Drug Design Strategies for the Treatment of Human African Trypanosomiasis

 

 

Phosphofructokinase Structure Enables Rational Drug Design

 

Phosphofructokinase-1

Figure 1. Surface representation of T. brucei PFK-1

Trypanosoma brucei is a unicellular parasitic protozoan that infects human and animal hosts and causes the fatal disease, Human African trypanosomiasis (HAT), also known as African sleeping sickness. HAT is endemic in over thirty countries, where approximately 60 million people are exposed to the parasite (World Health Organization 2006). Martinez-Oyanedel et al. (2006) solved the first crystal structure of a eukaryotic phosphofructokinase from the trypanosome, T. brucei. Phosphofructokinase (PFK) is an important enzyme in glycolysis. The structure of T. brucei PFK will enable rational design analysis of anti-parasitic drugs that target glycolytic energy production in this parasite.

Author: Helen Mashalidis| helenm@email.arizona.edu | Biochemistry 462B Honors "Metabolism in the News | The University of Arizona | Instructor: Dr. Don P. Bourque| Last revised: 05-02-07